The DOI matches its Crossref record; 12 of the 14 references it cites were found in a registry or an index.
Seroprevalence of immunoglobulin M and G antibodies against SARS-CoV-2 in China
Open accessAbstract
Detection of asymptomatic or subclinical novel human coronavirus SARS-CoV-2 infection is critical for understanding the overall prevalence and infection potential of COVID-19. To estimate the cumulative prevalence of SARS-CoV-2 infection in China, we evaluated the host serologic response, measured by the levels of immunoglobulins M and G in 17,368 individuals, in the city of Wuhan, the epicenter of the COVID-19 pandemic in China, and geographic regions in the country, during the period from 9 March 2020 to 10 April 2020. In our cohorts, the seropositivity in Wuhan varied between 3.2% and 3.8% in different subcohorts. Seroposivity progressively decreased in other cities as the distance to the epicenter increased. Patients who visited a hospital for maintenance hemodialysis and healthcare workers also had a higher seroprevalence of 3.3% (51 of 1,542, 2.5-4.3%, 95% confidence interval (CI)) and 1.8% (81 of 4,384, 1.5-2.3%, 95% CI), respectively. More studies are needed to determine whether these results are generalizable to other populations and geographic locations, as well as to determine at what rate seroprevalence is increasing with the progress of the COVID-19 pandemic. Serologic surveillance has the potential to provide a more faithful cumulative viral attack rate for the first season of this novel SARS-CoV-2 infection.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“SARS-CoV-2 seroprevalence in our study is comparable with estimates from large population-based serosurveys in China, Switzerland, Spain, and the United States after the initial epidemic peak and after many tens of thousands of deaths (9, 10, 17, 18).”
From Seroprevalence of anti–SARS-CoV-2 IgG antibodies in Kenyan blood donors (2021) · cites this paper as [17]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30183-5 · Cited by 48,884
Self-citationClinical characteristics of coronavirus disease 2019 in China
Guan, W.-J., Ni, Z.-Y., Hu, Y., Liang, W.-H., Ou, C.-Q., He, J.-X., Liu, L., Shan, H., Lei, C.-L., Hui, D. S. C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2002032 · Cited by 30,246
A novel coronavirus from patients with pneumonia in China, 2019
Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J., Zhao, X., Huang, B., Shi, W., Lu, R., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001017 · Cited by 28,244
Wang, D., Hu, B., Hu, C., Zhu, F., Liu, X., Zhang, J., Wang, B., Xiang, H., Cheng, Z., Xiong, Y., et al. (2020) · JAMA · doi:10.1001/jama.2020.1585 · Cited by 20,148
La certeza de lo impredecible: Cultura Educación y Sociedad en tiempos de COVID19
Martínez González, M. (2020) · DSPACE System - Metalibrary (University of the Coast) · Cited by 18,463
Antibody responses to SARS-CoV-2 in patients with COVID-19
Long, Q.-X., Liu, B.-Z., Deng, H.-J., Wu, G.-C., Deng, K., Chen, Y.-K., Liao, P., Qiu, J.-F., Lin, Y., Cai, X.-F., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0897-1 · Cited by 2,876
Self-citationSARS-CoV-2 Infection in Children
Lü, X., Zhang, L., Du, H. N., Zhang, J., Li, Y. Y., Qu, J., Zhang, W., Wang, Y., Bao, S., Li, Y., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmc2005073 · Cited by 2,423
The Empirical Distribution Function with Arbitrarily Grouped, Censored and Truncated Data
Turnbull, B. W. (1976) · Journal of the Royal Statistical Society Series B (Statistical Methodology) · doi:10.1111/j.2517-6161.1976.tb01597.x · Cited by 1,835
Hu, Z., Song, C., Xu, C., Jin, G., Chen, Y., Xu, X., Ma, H., Chen, W., Lin, Y., Zheng, Y., et al. (2020) · Science China Life Sciences · doi:10.1007/s11427-020-1661-4 · Cited by 1,429
Self-citationA Novel Coronavirus Emerging in China — Key Questions for Impact Assessment
Munster, V. J., Koopmans, M., van Doremalen, N., van Riel, D. A. J., & de Wit, E. (2020) · New England Journal of Medicine · doi:10.1056/nejmp2000929 · Cited by 1,418
Cited by
Sorted by citations
Items 301–400 of 405
Moon, S. H., Kim, S. C., Kim, B. W., Park, G.-J., Chai, H. S., Kim, Y. M., Kim, H. S., & Park, H. S. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e14564 · Cited by 2
COVID-19 infection and seroconversion rates in healthcare workers in Lebanon: An observational study
Helou, M. C., Zoghbi, S., Osta, N. E., Mina, J., Mokhbat, J., & Husni, R. (2023) · Medicine · doi:10.1097/md.0000000000032992 · Cited by 3
A community based seroprevalence of SARS‐CoV‐2 antibodies in Somali Region, Eastern Ethiopia
Yared, S., Abera, T., Ali, S. M., Muhummed, A. M., Ibrahim, M. A. E.-S., Hussen, A., Hattendorf, J., Zinsstag, J., & Tschopp, R. (2024) · Immunity Inflammation and Disease · doi:10.1002/iid3.1148 · Cited by 2
Анатольевна, Б. А., Константиновна, Ш. Э., Захарова, Е. Н., Ивановна, Ч. А., Григорьевна, К. З., Шоуа, И. Б., Давыдова, Т. В., Кушлинский, Н. Е., Валентиновна, Б. И., Osipova, N. G., et al. (2023) · Immunologiya · doi:10.33029/0206-4952-2023-44-6-776-787 · Cited by 2
Caldrer, S., Accordini, S., Mazzi, C., Tiberti, N., Deiana, M., Matucci, A., Rizzi, E., Tais, S., Filippo, F., Verzè, M., et al. (2024) · Vaccines · doi:10.3390/vaccines12030230 · Cited by 2
Pinto, J. P. G., Magalhaes, P. C., Figueiredo, G. M., Alves, D., & Angel, D. M. S. (2020) · medRxiv · doi:10.1101/2020.08.11.20173039 · Cited by 2
Seroreactivity to SARS-CoV-2 in individuals attending a university campus in Bogotá ColombiaPreprint
González, J. M., Santos‐Barbosa, J. C., Jaller, C., Otalora, G., Hernandéz, L. J., Guevara‐Suarez, M., & Restrepo, S. (2021) · medRxiv · doi:10.1101/2021.03.15.21253609 · Cited by 2
Maternal SARS-CoV-2 IgG provides limited protection for their infantsPreprint
Wang, X., Yang, P., Zheng, J., Pin, L., Wei, C., Guo, J., Zhang, Y., & Zhao, D. (2020) · doi:10.21203/rs.3.rs-60621/v1 · Cited by 2
Covid-19 : Natural immunity versus vaccine immunityPreprint
Banoun, H. (2021) · doi:10.32388/dp264j · Cited by 1
Seabra, S. G., Merca, F., Pereira, B., Fonseca, I., de Carvalho, A. C. C., Brito, V., Alves, D. A., Libin, P., Martins, M. D. R. O., Miranda, M., et al. (2024) · Frontiers in Public Health · doi:10.3389/fpubh.2024.1326125 · Cited by 1
Mapping the viral battlefield: SARS-CoV-2 infection dynamics among healthcare workers in Brazil
Gasparoto, A. L. D. B., Graeff, S. V.-B., Santiago, W. M. S., da Silva, D. G., Santos, T., Paulino, L. M., Fava, W. S., Reis, F. P., Stutz, C., França, A. D. O., et al. (2025) · Human Resources for Health · doi:10.1186/s12960-024-00968-z · Cited by 1
Dassaye, R., Chetty, T., Daniels, B. B., Ramraj, T., Gaffoor, Z., Spooner, E., Mthethwa, N., Nsibande, D. F., Magasana, V., Mohlabi, K., et al. (2025) · Frontiers in Public Health · doi:10.3389/fpubh.2025.1548945 · Cited by 1
SARS-CoV-2 Antibody Seroprevalence in Wuhan, China, from 23 April to 24 May 2020
Han, H. W., Yi, J., Cheng, G., Jiang, W., Brożek, G. M., Jiang, Y., Zhu, C., & Xia, Y. (2021) · mSphere · doi:10.1128/msphere.01062-20 · Cited by 1
Osorio-Toro, L. M., Bonilla-Bonilla, D. M., Daza-Arana, J. E., Aristizábal, J. C., Valencia, J. C. A., & Ramírez, R. (2023) · International Journal of General Medicine · doi:10.2147/ijgm.s396357 · Cited by 1
Panorama da infecção pelo SARS-COV-2 no Centro de Progressão Penitenciária do Butantan
Andrade, S. G. D. A., Andrade, F., Silva, A., Cardoso, M. R. A., Ferraz, G. R., de Barros, E. N. C., Braga, P. E., Cristófalo, M. M., Vieira, J., Lopes, C. D. S., et al. (2023) · Revista de Saúde Pública · doi:10.11606/s1518-8787.2023057004717 · Cited by 1
Dhaouadi, S., Letaief, H., Hechaichi, A., Safer, M., Moussa, R., Bouhali, R., Letaief, F., Abdelkader, L., Salah, H. B., Mili, N. E., et al. (2023) · Epidemiologia · doi:10.3390/epidemiologia4020020 · Cited by 1
Differences in SARS-COV-2 seroprevalence in the population of Cusco, Peru
Huamaní, C., Concha-Velasco, F., Velásquez, L., Antich, M. K., Cassa, J., Palacios, K., Bernable-Villasante, L., Giraldo-Alencastre, G., Benites-Calderon, E., Mendieta-Nuñez, S., et al. (2023) · Global Epidemiology · doi:10.1016/j.gloepi.2023.100131 · Cited by 1
Analysis of SARS-CoV-2 antibody seroprevalence in Northern Ireland during 2020–2021
Greene, M. K., Smyth, P., English, A. R., McLaughlin, J. B., Bucholc, M., BAILIE, J. R., McCarroll, J., McDonnell, M., Watt, A. P., Barnes, G., et al. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e24184 · Cited by 1
Rate, I. M. B., Suwiti, N. K., Suardana, I. B. K., & Besung, I. N. K. (2025) · Farm Animal Health and Nutrition · doi:10.58803/fahn.v4i1.65 · Cited by 1
Keller, N., & Jenny, M. A. (2020) · MDM Policy & Practice · doi:10.1177/2381468320963068 · Cited by 1
Vacinas contra a infecção pelo SARS-CoV-2
Silva, T. C., de Andrade, A. B. M. D. G., Barral-Neto, M., & Boaventura, V. S. (2020) · EDUFBA eBooks · doi:10.9771/9786556300443.009 · Cited by 1
Testes diagnósticos na COVID-19
Boaventura, V. S., Silva, T. C., Santos, L. A., de Oliveira, M. S., Khouri, R., Barral, A. M. P., & Barral‐Netto, M. (2020) · EDUFBA eBooks · doi:10.9771/9786556300443.008 · Cited by 1
A dual antibody test for accurate surveillance of SARS-CoV-2 exposure rates
LeBlanc, E. V., & Colpitts, C. C. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100223 · Cited by 1
Bunces, D., Serrano-Arévalo, K., Guevara, C. M. M., Simancas‐Racines, D., & Salazar, M. F. (2021) · Práctica Familiar Rural · doi:10.23936/pfr.v6i1.193 · Cited by 1
Severe acute respiratory syndrome coronavirus 2 seroprevalence survey among 10,256 workers in Kuwait
Altawalah, H., Alfouzan, W. A., Dhar, R., Alali, W. Q., Bastaki, H., Al-Fadalah, T., Al-Ghimlas, F., Rabaan, A. A., & Ezzikouri, S. (2021) · Journal of Clinical Virology Plus · doi:10.1016/j.jcvp.2021.100017 · Cited by 1
The front-line during the coronavirus disease 2019 pandemic: healthcare personnel
Kang, M., & Perl, T. M. (2021) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000734 · Cited by 1
Seroprevalence of Immunoglobulin-G Antibody Among Confirm Cases of COVID-19
Prakash, O., Solanki, B., Sheth, J. K., Shah, T., Kadam, M., Vyas, S., Shukla, A. A., Pethani, J., & Tiwari, H. (2021) · Cureus · doi:10.7759/cureus.17956 · Cited by 1
Konstantinidis, T. G., Zisaki, S., Mitroulis, I., Cassimos, D. C., Nanousi, I., Kontekaki, E. G., Petrakis, V., Parrisi, K., Fotiadou, E., Linardou, A., et al. (2021) · GERMS · doi:10.18683/germs.2021.1274 · Cited by 1
SARS-CoV-2 Serology Testing in an Asymptomatic, At-Risk Population: Methods, Results, Pitfalls
Heyming, T. W., Bacon, K., Lara, B., Knudsen-Robbins, C., Tongol, A., & Sanger, T. D. (2021) · Infectious Disease Reports · doi:10.3390/idr13040082 · Cited by 1
Seroprevalence of Antibodies to SARS-CoV-2 in Guangdong Province, China between March to June 2020
Xiao, C., Leung, N., Cheng, Y., Lei, H., Ling, S., Lin, X., Tao, R., Huang, X., Guan, W., Yang, Z., et al. (2021) · Pathogens · doi:10.3390/pathogens10111505 · Cited by 1
Self-citationBlbas, S. S. I., Ahmad, H. A., Hawezy, D. J., Shawgery, H., & Bahaddin, H. N. (2021) · ARO-The Scientific Journal of Koya University · doi:10.14500/aro.10831 · Cited by 1
Masoudi, S., Angoorani, H., Fesharaki, M. J., Zoghalchi, B., Jahani, P., & Urumieh, M. (2022) · International Journal of Epidemiology and Health Sciences · doi:10.51757/ijehs.3.1.2022.247403 · Cited by 1
Sandagdorj, A., Tsedenbal, N., Namuutsetseg, B., Ganbold, S., Chimedregzen, K., Munkhbayar, U., Baatar, G., Chuluundorj, K., Badarch, D., Bazarjav, P., et al. (2023) · Infectious Diseases Diagnosis & Treatment · doi:10.29011/2577-1515.100210 · Cited by 1
Covid-19: Natural Immunity Versus Vaccine Immunity Abstract
Banoun, H. (2021) · Annals of Immunology & Immunotherapy · doi:10.23880/aii-16000153
SARS-CoV-2 Seroprevalence Studies: A Rapid ReviewPreprint
Chess, K., Jacobson, T., Smith, L. E., Miller, C. H., Hirschhorn, L. R., & Huffman, M. D. (2020) · doi:10.21203/rs.3.rs-56014/v1 · Cited by 1
Diegoli, H., Conzatti, V. S., Mazin, S. C., Safanelli, J. A., Dellatorre, L. D. C., Bett, K., Radtke, R. E., Wollmann, G. M., Lima, H. D. N., de França, P. H. C., et al. (2021) · medRxiv · doi:10.1101/2021.02.08.21251009 · Cited by 1
Sero-prevalence of SARS-CoV-2 Antibody Among Adults in the General Population in Diredawa, EthiopiaPreprint
Shaweno, T., Abdulhamid, I., Bezabih, L., Teshome, D., Derese, B., Tafesse, H., & Shaweno, D. (2021) · Research Square · doi:10.21203/rs.3.rs-266413/v1 · Cited by 1
CRISPR/Cas12a-based SARS-CoV-2 Rapid Visual Detection and Clinical ApplicationPreprint
Xu, J., Wang, X., Ma, X., Sun, Z., Liu, Q., Li, M., & Wang, H. (2022) · doi:10.22541/au.165147850.00008025/v1 · Cited by 1
The infectious vaccines against SARS-CoV-2 already existPreprint
Ding, J. (2020) · doi:10.31219/osf.io/urzs9 · Cited by 1
Ray, A., Singh, K., Mehdi, F., Chattopadhyay, S., Jadon, R. S., Nischal, N., Soneja, M., Sethi, P., Meena, V. P., Trikha, A., et al. (2022) · medRxiv · doi:10.1101/2022.08.19.22278876 · Cited by 1
Development of a MALDI‐TOF Mass Spectrometry Test for Viruses
Iles, R. K., Iles, J. K., & Zmuidinaite, R. (2023) · doi:10.1002/9781119814085.ch5 · Cited by 1
Liu, Y., Gong, W., Clifford, S., Sundaram, M. E., CMMID-COVID19 Working Group, Jit, M., Flasche, S., & Klepac, P. (2020) · medRxiv · doi:10.1101/2020.06.27.20141440
SARS-CoV-2 Seroprevalence in Relation to Timing of SymptomsPreprint
Ebinger, J. E., Botwin, G. J., Albert, C. M., Alotaibi, M., Arditi, M., Berg, A. H., Binek, A., Botting, P. G., Fert‐Bober, J., Figueiredo, J. C., et al. (2020) · medRxiv · doi:10.1101/2020.08.02.20166876
Self-citationCheng, H., Chen, H., Li, Y., Zheng, P., Gu, D., He, S., Ma, D., Wang, R., Han, J., Lu, Z., et al. (2020) · medRxiv · doi:10.1101/2020.08.11.20172452
Designing a multi-layered surveillance approach to detecting SARS-CoV-2: A modelling study
Liu, Y., Gong, W., Clifford, S., Sundaram, M. E., CMMID COVID-19 Working Group, Jit, M., Flasche, S., & Klepac, P. (2020) · Wellcome Open Research · doi:10.12688/wellcomeopenres.16256.1
Seroprevalence of immunoglobulin M and G antibodies against SARS-CoV-2 in ophthalmic patientsPreprint
Li, S., Qiu, Y., Tang, L., Wang, Z., Cao, W., Xu, G., & Sun, X. (2020) · medRxiv · doi:10.1101/2020.09.22.20198465
Liu, T., Wu, S., Tao, H., Zeng, G. Q., Zhou, F., & Wang, X. (2020) · doi:10.21203/rs.3.rs-99748/v1
SARS-Cov-2 Seroprevalence in a French Kidney Transplant Center Located Within a “High-risk” Zone
Caillard, S., Benotmane, I., Meidinger, C., Jegou, V., Ludwiller, S., Rihon, A., Desmarquets, A., Steinmetz, L., Morvan, M., Kedjam, K., et al. (2021) · Transplantation · doi:10.1097/tp.0000000000003766
Lehetőségek és buktatók a SARS-CoV-2-antigén és az ellene termelt antitestek kimutatásában
Medgyaszai, M., Péterfi, Z., & Valkó, A. (2021) · Orvosi Hetilap · doi:10.1556/650.2021.32210
SARS-COV-2 specific antibody prevalence among doctors of Emergency in Mayo Hospital, Lahore
Maqbool, T., Jehangir, H. M. S., Ahmad, M., Jamil, S., Saleem, S. U., & Siddique, T. (2020) · Pakistan Postgraduate Medical Journal · doi:10.51642/ppmj.v31i02.332
The Infectious Vaccines against SARS-CoV-2 Already Exist
Ding, J. (2020) · International Journal of Biochemistry & Physiology · doi:10.23880/ijbp-16000188
COVID-19 Seroprevalence among Healthcare Workers in a University Hospital in Southeastern Turkey
Karslığil, T., & Akdoğan, H. (2021) · European Journal of Therapeutics · doi:10.5152/eurjther.2021.20106
Covid-19 Pandemisine Seroepidemiyolojik Yaklaşım
Alpay, E. E., & Ünal, B. (2021) · STED / Sürekli Tıp Eğitimi Dergisi · doi:10.17942/sted.892713
Swami, S. K., Chauhan, N. K., Goyal, S., Verma, A., & Biyani, S. (2021) · Indian Journal Of Applied Research · doi:10.36106/ijar/8102221
Plasma cell-free DNA promise disease monitoring and tissue injury assessment of COVID-19Preprint
Jin, X., Wang, Y., Xu, J., Li, Y., Cheng, F., Luo, Y., Zhou, H., Lin, S., Xiao, F., Zhang, L., et al. (2021) · medRxiv · doi:10.1101/2021.07.19.21260139
Self-citationSero-Epidemiological Survey and Profile of SARSCov- 2 Infection in Cabo Verde
Mendonça, M. D. L. L. (2021) · American Journal of Biomedical Science & Research · doi:10.34297/ajbsr.2021.13.001835
Zhang, Y., Liu, X.-Z., Zhang, Z., Zhou, T., Zhang, X., Yang, H., Tan, M., Hu, N., Shi, S.-F., Wang, F., et al. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3932259
Rapid Serological Testing for Managing the COVID-19 Pandemic: A Review
Faheem, S. M., D’Mello, J., Kaleem, S. M., Burra, P. V. L. S., & Siddiqui, K. (2021) · The Open Biomarkers Journal · doi:10.2174/1875318302111010099
SARS-CoV-2 seroprevalence among blood donors, Chongqing, China, January 1 to May 31, 2020
Wang, S., Song, M., Liu, Q., & Yao, C. (2022) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2022.01.004
Mahavadi, S., Gujjarlapudi, D., Veeraiah, N., Hassan, N., & Duvvur, N. R. (2021) · IP Indian Journal of Immunology and Respiratory Medicine · doi:10.18231/j.ijirm.2021.048
Özkurt, S. (2021) · Northern Clinics of Istanbul · doi:10.14744/nci.2021.62447
Zandian, H., Moghadam, T. Z., Habibzadeh, S., & Pourfarzi, F. (2022) · The Open Public Health Journal · doi:10.2174/18749445-v15-e2201140 · Cited by 1
Fernandes, G., Paixão, P., Brum, L., Padrão, T. G., Correia, J., Albuquerque, J., Pulido, C., Nave, M., Timóteo, T., Rodrigues, T., et al. (2022) · Cureus · doi:10.7759/cureus.22428
Pádua, A., Alvarelhão, J., Gama, M., Figueiredo, R. M., & Alves, V. (2021) · Revista Portuguesa de Saúde Ocupacional · doi:10.31252/rpso.03.08.2021
Ray, A., Singh, K., Chattopadhyay, S., Mehdi, F., Batra, G., Kumari, A., Agarwal, A., Bhavesh, M., Sahni, S., Chaithra, R., et al. (2020) · doi:10.2196/preprints.23937
Swami, S. K., Chauhan, N. K., Goyal, S., Verma, A., & Biyani, S. (2021) · Indian Journal Of Applied Research · doi:10.36106/ijsr/8601137
Royo, C., Robert-Montaner, Ï., Vilanova, D., Baillés, E., Serrano-Pons, J., Valero, O., Buldon, J. M., Bermudez-de-Castro, L., Mahía, E., Pujadas, J., et al. (2022) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-022-04141-8
Sars-Cov-2 seroprevalence among HIV patients under ART in Morocco, during the Covid-19 pandemic
(2021) · International Journal of Biology Pharmacy and Allied Sciences · doi:10.31032/ijbpas/2021/10.12.2060
Current clinical testing approach of COVID
Bhardwaj, M., & Kakkar, P. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-90280-9.00003-1
Serorreactividad al SARS-CoV-2 en trabajadores de un campus universitario en Bogotá, Colombia
González, J. M., Santos‐Barbosa, J. C., Jaller, C., Romero, G., Hernandéz, L. J., Guevara‐Suarez, M., & Restrepo, S. (2022) · Revista de la Academia Colombiana de Ciencias Exactas Físicas y Naturales · doi:10.18257/raccefyn.1590 · Cited by 2
Raygoza, N. P., Navarro-Olivos, E., Gallardo-Luna, M. D. J., Flores-Vargas, G., Sánchez-Navarro, M. D. R., Lara-Lona, E., Sandoval-Ramírez, E., Magos-Vázquez, F. J., & Díaz-Martínez, D. A. (2022) · Biomedical & Pharmacology Journal · doi:10.13005/bpj/2480
A sampling scheme for estimating the prevalence of a pandemic
Liu, Z., Yi, S., Dong, J. J., Liu, M., & Zhou, Y. (2023) · Communications in Statistics - Simulation and Computation · doi:10.1080/03610918.2023.2213425
Wu, B., Liu, B., Jiang, X., Yuan, Y., Qin, W., Qin, K., Mei, Q., Zhang, L., Zhang, H., Hu, G., et al. (2021) · Oncology and Translational Medicine · doi:10.1007/s10330-021-0488-8
Transplacental Transfer of SARS-COV-2 Antibodies
Badr, D. A., & Jani, J. C. (2023) · Springer eBooks · doi:10.1007/978-3-031-29136-4_10
Hultqvist, V., Bonnedahl, J., Edwardsson, J., Tjernberg, I., & Rydén, I. (2023) · Apmis · doi:10.1111/apm.13343
Vacina COVID-19: quanto valem os Anticorpos?
Peixoto, J. F., Vilaça, P. J., & Oliveira, S. (2022) · Revista Portuguesa de Saúde Ocupacional · doi:10.31252/rpso.07.05.2022
Jesmine, R., Jubaida, N., Baki, A. A., Giti, S., & Rahman, M. (2023) · Journal of Armed Forces Medical College Bangladesh · doi:10.3329/jafmc.v18i2.63992
Azangou‐Khyavy, M., Ghasemi, E., Ebrahimi, N., Rashidi, M., Abbasi‐Kangevari, M., Ahmadi, N., Khanali, J., Kazemi, A. S., Dilmaghani‐Marand, A., Farzi, Y., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-3143444/v1
Clinical characteristics, management, and prevention of coronavirus disease 2019
Guan, W., & He, J. (2023) · Frigid Zone Medicine · doi:10.2478/fzm-2023-0019
Dias, N. J. D., da Silva, M. P., Barbosa, M. S., Pereira, G. R., & Silva, D. R. (2023) · Revista da Associação Médica Brasileira · doi:10.1590/1806-9282.20230661 · Cited by 1
Analysis of SARS-CoV-2 Ig seroprevalence in Northern IrelandPreprint
Greene, M. K., Smyth, P., English, A. R., McLaughlin, J., Bucholc, M., BAILIE, J. R., McCarroll, J., McDonnell, M., Watt, A. P., Barnes, G., et al. (2023) · medRxiv · doi:10.1101/2023.09.19.23295776
Verma, A. K., Annapurna, Panchgaur, R., & Kumar, A. (2023) · International Journal of Community Medicine and Public Health · doi:10.18203/2394-6040.ijcmph20233775 · Cited by 1
Ribeiro, J. A. M., Marinho, L. D. C. S., Fonseca, S. G. C., D’Almeida, J. B., Massignan, C., & Lia, É. N. (2024) · Tempus Actas de Saúde Coletiva · doi:10.18569/tempus.v16i3.3065
Dynamics of formation of anti- bodies to SARS-CoV-2 after coronavirus infection in children
Bogomolova, I. K., & Peregoedova, V. N. (2024) · Perm Medical Journal · doi:10.17816/pmj41113-23
Screening and Analysis of SARS-CoV-2 Antibody Among Unvaccinated Blood Donors in Chongqing, China
Jiang, Y., Huang, L., Liao, H., Luo, C., Zhang, C., & Mao, W. (2024) · Disaster Medicine and Public Health Preparedness · doi:10.1017/dmp.2023.232
Bailón-Cuenca, J. A., Cortés-Sarabia, K., Legorreta-Soberanis, J., Alvarado-Castro, V. M., Juárez-Baltazar, U., Sánchez-Gervacio, B. M., Vences-Velázquez, A., Leyva‐Vázquez, M. A., Moral-Hernández, Ó. D., & Illades‐Aguiar, B. (2024) · BMC Infectious Diseases · doi:10.1186/s12879-024-09435-5 · Cited by 1
Scaling, Power-Law First Return Times, and Non-Ergodicity
Lambert, D. R. (2022) · University of North Texas Digital Library (University of North Texas) · doi:10.12794/metadc1987323
Flow cytometric analysis of the SARS coronavirus 2 antibodies in human plasma
Fang, J., Shrestha, L., & Beland, F. A. (2025) · Scientific Reports · doi:10.1038/s41598-025-92389-8
Braeye, T., Pauw, R. D., Geebelen, L., Abrams, S., Desombere, I., Hens, N., Hammami, N., Roelants, M., & Herzog, S. A. (2025) · medRxiv · doi:10.1101/2025.07.02.25330709
National and sub-national sero-epidemiology of immunoglobulin G against SARS-CoV-2 in Iran in 2021
Azangou‐Khyavy, M., Ghasemi, E., Ebrahimi, N., Rashidi, M., Abbasi‐Kangevari, M., Ahmadi, N., Khanali, J., Kazemi, A. S., Dilmaghani‐Marand, A., Farzi, Y., et al. (2025) · PLoS ONE · doi:10.1371/journal.pone.0313795
Johnson, M. G., Strizki, J., Hilbert, D. W., Zhang, Y., Carmelitano, P., Brown, M. L. H., Wolf, D. J., Paschke, A. A., & Anda, C. S. D. (2025) · Virology · doi:10.1016/j.virol.2025.110710
Bailón-Cuenca, J. A., Cortés-Sarabia, K., Legorreta-Soberanis, J., Alvarado-Castro, V. M., Juárez-Baltazar, U., Sánchez-Gervacio, B. M., Vences-Velázquez, A., Vázquez, M. A. L., Moral-Hernández, Ó. D., & Illades‐Aguiar, B. (2024) · Figshare · doi:10.6084/m9.figshare.26027458
Metadata
- Authors
- Xu, X., Sun, J., Nie, S., Li, H., Kong, Y., Liang, M., Hou, J., Huang, X., Li, D., Ma, T., Peng, J., Gao, S., Shao, Y., Zhu, H., Lau, J. Y.-N., Wang, G., Xie, C., Jiang, L., Huang, A., Yang, Z., Zhang, K., & Hou, F. F.
- Affiliations
- Nanfang Hospital (CN)
- Kingmed Diagnostics (CN)
- First People's Hospital of Foshan (CN)
- Honghu People’s Hospital (CN)
- First People's Hospital of Jingzhou (CN)
- Jingzhou Central Hospital (CN)
- Honghu Hospital of Traditional Chinese Medicine (CN)
- Hong Kong Polytechnic University (HK)
- Tsinghua University (CN)
- University of Electronic Science and Technology of China (CN)
- Chongqing Medical University (CN)
- Macau University of Science and Technology (MO)
- Corresponding author
- Huang, Ailong
- Yang, Zhenglin
- Zhang, Kang
- Hou, Fan Fan
- ORCID
- Venue
- Nature Medicine
- Published
- 2020-06-05
- Volume
- 26
- Issue
- 8
- Pages
- 1193-1195
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W3033219406
- Cited by
- 405
- References
- 14
- Citations by year
- 2026: 2 · 2025: 9 · 2024: 16 · 2023: 28 · 2022: 58 · 2021: 174 · 2020: 118
- FWCI
- 12.42
- Type
- journal article
- Language
- en
- Update notices
- correction (2020-08-18)
- Open access
- bronze
- doi.org
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Fundo para o Desenvolvimento das Ciências e da Tecnologia (0035/2020/A)
- Guangzhou Regenerative Medicine and Health Guangdong Laboratory (2020GZR110306001, 2018GZR110102004, 2018GZR0201003)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 detection and testing
- Physical Sciences › Mathematics › Modeling and Simulation › COVID-19 epidemiological studies
- Keywords
- SARS-CoV-2, COVID-19 pandemic, seroprevalence, immunoglobulin M, IgG, serological surveillance, asymptomatic infection, Wuhan, hemodialysis patients, healthcare workers, regional variation
- MeSH terms
- Betacoronavirus, COVID-19, SARS-CoV-2, Antibodies, Viral, China, Female, Health Personnel, Humans, Immunoglobulin G, Immunoglobulin M, Male, Middle Aged, Pneumonia, Viral, Seroepidemiologic Studies, Coronavirus Infections, Pandemics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
